The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings indicate that, overall, transgender women exhibited a 2.56-fold lower risk of prostate cancer compared to cisgender men. Specifically, among TW on hormone therapy between ages 50-64, we observed a 2.06-fold decrease in risk. Contrary to the previous perception of prostate cancer being rare in transgender women, our study suggests that it may not be as uncommon as previously believed.
Prostate cancer and prostatic diseases. 2024 Feb 07 [Epub ahead of print]
Matthew Loria, David Gilbert, Tomasz Tabernacki, Mart Andrew Maravillas, Megan McNamara, Shubham Gupta, Kirtishri Mishra
University Hospitals, Urology Institute, Cleveland, OH, USA. ., University Hospitals, Urology Institute, Cleveland, OH, USA., Case Western Reserve University School of Medicine, Cleveland, OH, USA.